Clinical Guest Contributors

  1. The Myth Of Disruptive Innovation In Clinical Trials: Time For A More Disciplined Approach
    11/21/2019

    At the outset, let me state for the record that I’m a big advocate for change. My threshold for accepting “that’s the way we’ve always done things” is actually quite low. But I confess that I’m getting a bit dizzy, dismayed, and, to be frank, disappointed with all the so-called “disruptive innovation” taking place in the industry. First and foremost, I don't really think that anything taking place really qualifies as disruptive.

  2. Putting Patients First In Clinical Trial Designs — A Multifaceted Approach
    11/19/2019

    Patient enrollment is critical to the success of a clinical trial and yet clinical trial designs are not always conducive to the participation of cancer patients. According to a study by Dr. Joseph Unger and colleagues at Fred Hutchinson Cancer Research Center, more than half (55.6 percent) of all cancer patients do not participate in trials because no appropriate trial is available for the patient’s cancer type and stage at the center where they are being treated. Further, when a trial was available, an additional 21.5 percent were ineligible due to exclusion criteria.

  3. 5 Actionable Steps To Expedite Clinical Trial Agreements
    11/14/2019

    Clinical trial agreements have been notorious for delaying study start-up. This challenge remains even as different players in the industry strive to speed up clinical trial agreement finalization through efforts such as standardization of clinical trial agreement templates and the adoption of contract automation tools.

  4. SOP Remediation: When Reinventing The Wheel Is The Best Approach
    11/12/2019

    When faced with scenarios that demand SOP remediation (outsourcing, mergers, acquisition), a common instinct is to do whatever possible to salvage the work that’s been done, believing this is the most efficient approach. However, repurposing processes, written content, templates, etc., can be the worst possible and most expensive approach when you factor in time, human resources, and long-term outcomes.

  5. 4 Tips For Successful Collaboration With Your EU Qualified Person (QP)
    11/8/2019

    Qualified Persons (QPs) are responsible for the certification of clinical trial materials in the EU and therefore are an essential link in U.S. sponsors’ supply chains. Indeed, engaging QPs well before the clinical trial material needs to be certified not only assures a smooth release process and trial start-up but mitigates pitfalls associated with unanticipated technical, quality, and regulatory challenges.

  6. Hybrid Decentralized Trials: Using Technology To Create More Patient-Centric Studies
    11/5/2019

    While it is not a new trend, the spotlight on digital innovation has grown brighter over the last year, with executives from all sides of the clinical research industry seeking technology solutions to improve the clinical trial experience for sites and patients alike. It was a recurring theme at this year’s Society for Clinical Research Sites (SCRS) Global Site Solutions Summit, with several sessions that addressed technological advancement and attendee feedback requesting more discussion on the topic at future Summits.

  7. Driving Innovation: Blockchain Adoption For Clinical Trials Optimization
    10/31/2019

    Pharmaceutical companies and research institutions are feeling the pressure to reduce the time, financial, and other resource costs associated with conducting clinical trials. With the influx of emerging applications for technologies such as machine learning, robotics and automation, and blockchain and other distributed ledger technologies (DLTs), many see a new path to more efficient and effective processes that can address the challenges faced today.

  8. The EU Qualified Person (QP) Demystified: Fool-Proofing Your EU Phase 1 Trial
    10/29/2019

    For U.S. sponsors planning to conduct clinical trials in the EU, Qualified Persons (QPs) may at times be perceived as a challenge to overcome, because their role and responsibilities are not fully understood. Conversely, part of the QP’s role is to support clinical trials in the EU by certifying compliant clinical trial materials while protecting public health.

  9. Preparing For Health Authority Inspections: 4 Keys To Inspection Readiness
    10/22/2019

    Health authority inspections are one of the most stress-inducing experiences a sponsor, CRO, or site will go through. The mere mention of inspections is enough to throw some people into full on panic-mode. While preparing for an inspection will never be a care- and stress-free process, there are appropriate ways to get your organization ready for one without adding another layer of stress and frustration.

  10. 5 Narrative Elements That Will Reveal The Masterpiece In Your TMF
    10/15/2019

    In response to the increasing opacity of the trial master file (TMF), clinical trial decision makers have embraced quantitative metrics as a way of characterizing and understanding the health of a TMF. Quantitative metrics are easily generated through the reporting functionality of a modern electronic TMF (eTMF) and appear to add value by leveraging the data passively generated through modern clinical applications. Although helpful to address specific concerns, especially those related to completeness, these metrics are often unintuitive and do not readily describe the aspects of a clinical trial most instrumental for TMF health.